Biovitrum creates new business unit and secures multi-year agreement with Amgen

BIOVITRUM CREATES NEW BUSINESS UNIT AND SECURES MULTI-YEAR AGREEMENT WITH AMGEN STOCKHOLM, SWEDEN - October 21, 2003 - Biotechnology company Biovitrum has established a new business unit, Biovitrum Biopharmaceuticals, with the purpose of strengthening its position as a supplier of process development and contract manufacture of recombinant proteins. The unit will be headed by Hans Örström who will also become a member of the Biovitrum Senior Management team. A three-year partnership was recently initiated with US biotechnology company Amgen, which has commissioned Biovitrum to develop cost- efficient commercial production processes for future protein-based pharmaceuticals. Amgen has conducted research and development in recombinant proteins for some 20 years and is currently the world's largest biotechnology company. Biovitrum Biopharmaceuticals has extensive experience and broad know-how in both process development and the production of recombinant proteins in preparation for pre-clinical and clinical trials. The agreement will grant Amgen access to Biovitrum's expertise in securing stable production processes for future launches of protein-based pharmaceuticals. "This is an important milestone for Biovitrum Biopharmaceuticals. We are entering a multi-year collaboration with the world's most successful company in protein-based pharmaceuticals," says Hans Örström. "Naturally, the partnership strengthens our position as a supplier of high-quality process development, giving the new business unit a favorable start." Biovitrum Biopharmaceuticals' other customers include Pfizer, Active Biotech and Wyeth. Biovitrum is among the pioneers of protein-based pharmaceuticals. As part of the former Kabivitrum, Biovitrum's researchers were involved with the development of recombinant growth hormone in the early 1980s. Since then, the group has developed several processes for clinical materials and for the commercial production of recombinant protein-based pharmaceuticals, such as ReFacto (recombinant factor VIII). ReFacto, which is used in the treatment of hemophilia, has been produced by Biovitrum and marketed by US pharmaceuticals company Wyeth since 1999. Biovitrum enquiries: Mikael Widell, SVP Communications Biovitrum AB Tel +46 8 697 20 85 Mobile +46 70 311 99 60 Mikael.widell@biovitrum.com Notes to editors: About Biovitrum Biovitrum is a privately held biotech company active in the discovery and development of drugs to treat metabolic diseases, such as type 2 diabetes and obesity, and in the process development and contract manufacturing of protein therapeutics. The company has a strong intellectual property and technology platform, with a number of compounds in pre-clinical and clinical development. Biovitrum is one of the largest biotech companies in Europe with more than 575 employees. Annual revenues, including royalties and contract service fees, finance the major part of the annual research budget. For more information, please visit Biovitrum's website at www.biovitrum.com. ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2003/10/28/20031028BIT00390/wkr0001.doc http://www.waymaker.net/bitonline/2003/10/28/20031028BIT00390/wkr0002.pdf

About Us

Biovitrum is one of the larger biopharma companies in Europe. With operations in Sweden and in the UK Biovitrum conducts research and develops pharmaceuticals for unmet medical needs both for common diseases and conditions that affect smaller patient populations.Biovitrum focuses on drugs for the treatment of obesity, diabetes, inflammation and blood diseases as well as a number of well defined niche indications. Biovitrum develops and produces protein-based drugs on a contractual basis and markets a range of specialist pharmaceuticals primarily in the Nordic countries. Biovitrum has approximately 500 employees.

Subscribe